Shares of Nuvalent surged 39% to a record high of $123 on the Nasdaq on June 9 after GlaxoSmithKline (GSK) agreed to acquire the cancer drug developer for $10.6 billion, according to livemint.com. The acquisition aims to strengthen GSK's position in precision oncology as it rebuilds its cancer drug portfolio.
The deal was announced on June 9, with GSK agreeing to purchase Nuvalent to enhance its oncology offerings. The British pharmaceutical company had previously swapped its oncology business for Novartis’ vaccines division in 2014 but has since been focused on expanding its cancer drug pipeline. The acquisition of Nuvalent is a strategic move to regain footing in the oncology market.
This acquisition is significant as it bolsters GSK’s presence in the precision oncology sector, a field that has seen increasing investment and competition. The $10.6 billion deal ranks among the larger pharmaceutical acquisitions this year and reflects the ongoing consolidation in the cancer drug development space. GSK’s move follows a broader industry trend where major pharma companies seek to expand their oncology portfolios through acquisitions.
Nuvalent’s shares closing at $123 on June 9 represent a substantial market reaction to the deal announcement. The acquisition deal is expected to close later this year, subject to regulatory approvals and customary closing conditions, as per livemint.com.